Simple and Practical Mental Health

The BEST resource for mental health clinicians

  • REVIEWS
  • MENUS
  • RESOURCES
    • Side effect handouts
    • Patient handouts: Main page
    • How to find treatment resources
    • Rating scales and questionnaires for mental health clinicians
    • BEST books
    • BEST apps/ websites
  • NEWS
  • QUESTIONS?
  • DAILY EMAILS
  • FAQ
  • LOG IN
  • JOIN

Paliperidone (Invega®): Basic Information

Paliperidone extended-release (US brand name Invega® and generic) is a second-generation (“atypical”) antipsychotic. Here is basic information about this medication.


FDA-approved indications

1. Treatment of schizophrenia in adults and adolescents (ages 12-17)

2. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers and/or antidepressants.


Dosage

A. Schizophrenia (adults)

Initial: 6 mg/day
Recommended: 3 – 12 mg/day
Maximum: 12 mg/day

Recommended dose increments: 3 mg/day at intervals of more than 5 days after clinical assessment

Dose increases above 6 mg/day should be made only after clinical reassessment and generally should occur at intervals of more than 5 days

B. Schizophrenia (adolescents < 51 kg)

Initial: 3 mg/day
Recommended: 3 – 6 mg/day
Maximum: 6 mg/day

Recommended dose increments: 3 mg/day at intervals of more than 5 days after clinical assessment

C. Schizophrenia (adolescents ≥ 51 kg)

Initial: 3 mg/day
Recommended: 3 – 12 mg/day
Maximum: 12 mg/day

Recommended dose increments: 3 mg/day at intervals of more than 5 days after clinical assessment

d. Schizoaffective Disorder (adults)

Initial: 6 mg/day
Recommended: 3 – 12 mg/day
Maximum: 12 mg/day

Recommended dose increments: 3 mg/day at intervals of more than 4 days after clinical assessment

Paliperidone should be administered once daily. Tablets should be swallowed whole and should not be chewed, divided, or crushed.


Dosage forms and strengths

Tablets: 1.5 mg, 3 mg, 6mg, and 9 mg


Potential side effects

Please see THIS PAGE for a handout listing both the common and less common side effects of this medication along with the percentages of patients who report them. 


Please refer to Prescribing Information (see link below) for a complete discussion of dosage, administration, warnings and precautions, contraindications, etc.


Related Pages

Second-Generation Antipsychotics: Dose Equivalents

What should I be doing to monitor patients who are on an antipsychotic? (Free)

Antipsychotics and QTc prolongation

News: July 6, 2016. Make sure you are discussing increased risk of gynecomastia with risperidone (Free)

Paliperidone palmitate (Invega Sustenna®): Basic Information (Free)

Paliperidone palmitate 3-month (Invega Trinza®): Basic Information (Free)

Second-generation (“Atypical”) antipsychotics


References

Prescribing information for paliperidone extended-release (Invega®)


Copyright 2015, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.

Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.

Share this:

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email

Leave a Reply:Cancel reply

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter

Copyright 2016 to 2025: Simple and Practical Medical Education, LLC. All rights reserved.